

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 64295

Title: Thoracoscopic segmentectomy and lobectomy assisted by three-dimensional computed-tomography bronchography and angiography for the treatment of primary

lung cancer

Reviewer's code: 05408336

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2021-02-15

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-06-21 05:45

Reviewer performed review: 2021-07-04 01:59

Review time: 12 Days and 20 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	 [] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	 [] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

Authors reported the safety and feasibility of 3D-CTBA in performing VATS for lung cancers. These methods are interesting but several problems are included in this report. Major comments #1 Why this cohort is not including the segmentectomy in basal segment including S7, S8, S9, and S10? Criteria of segmentectomy should be described #2 If utility of 3D-CTBA was assessed in performing VATS for lung cancers, correctly. author should be comparing the data between before and after introduction of 3D-CTBA. #3 In Table 1, smoking history and comorbidity should be include in characteristic of patients. #4 Sizes of font are quite small in all Figures. #5 To assesses the safety and feasibility of 3D-CTBA in performing VATS for lung cancers, size of cohort is quite small to conclude those results. Size of cohort should be included limitation. #6 There are several misspellings in this paper. Line54: poteoperative ICU, Line 119: lymph node matastasis or small-cell lung canceris Lien 126:matastasis, Line 133: Patitents, Line256 poteoperative, Line273: to.assess